CopyMark Law Group
4.9/5
Drawing for DC PHARMA

USPTO serial 79366207

DC PHARMA

Reviewed by CopyMark Law Group

Reg. 7423994Status 700Registered
Filing date
Status date
Registration date
Jun 25, 2024
Examiner
MORRIS, KRISTINA KLOIBER
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DC PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alexander Butterman

Alexander Butterman Dunlap Bennett & Ludwig PLLC211 Church Street, SELeesburg, VA 20175United States

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic radiopharmaceutical preparations; vitamin tablets; medicines for human purposes, namely, medicines for the treatment of diabetes, obesity, cancer, oncological diseases, cardiovascular and cerebrovascular diseases, colds, cough, influenza, respiratory diseases and asthma, gastrointestinal diseases, genitourinary diseases, neurological diseases, allergies, headaches, insomnia, bacteria-based diseases, ocular disorders or diseases; biochemical medicines for the treatment of cancer; liquid herbal supplements; medicinal drinks; capsules sold empty for pharmaceuticals; pharmaceutical preparations, namely, antivirals; radioactive substances for medical purposes; pharmaceutical preparations for treating chemical imbalances; mixed biological preparations for the prevention and treatment of infectious diseases; isotopes for medical purposes; diagnostic reagents for medicinal use; diagnostic preparations for medical purposes; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; injectable pharmaceuticals for treatment of anaphylactic reactions; medicines made of Chinese traditional medicinal herbs; dietary supplementsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 28, 2024FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 11, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 10, 2024FIMPFINAL DISPOSITION PROCESSED—
Sep 25, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 25, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jun 25, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 16, 2024GPNXNOTIFICATION PROCESSED BY IB—
Apr 9, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 9, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 27, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 27, 2024OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 20, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 1, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 21, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 21, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 21, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 19, 2023RFNTREFUSAL PROCESSED BY IB—
Nov 28, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 28, 2023RFRRREFUSAL PROCESSED BY MPU—
Nov 23, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 22, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2023DOCKASSIGNED TO EXAMINER—
Apr 6, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 2, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 30, 2023LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Mar 30, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance